Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: Riociguat (Adempas(®️)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). The drug directly stimulates sGC in a nitric oxide independent manner, thereby increasing the sensitivity of sGC to nitric oxide, leading to increased cyclic guanosine monophosphate generation (a key signalling molecule involved in regulating vascular tone, proliferation, fibrosis and inflammation). Riociguat is the world's first approved pharmacotherapy for CTEPH, with its first global approval in this indication occurring in Canada. It has subsequently been approved in the USA for the treatment of patients with CTEPH and also received its first global approval in patients with PAH in the USA. It is undergoing regulatory review for these indications in Europe and for use in patients with CTEPH in Japan. This article summarizes the milestones in the development of riociguat, leading to its first global approvals in patients with CTEPH and PAH.

Answer: What is generic name of drug Adempas?

Question: The film starts on June 16, 1994 with Jesse meeting Celine on a train from Budapest and striking up a conversation with her. Jesse is going to Vienna to catch a flight back to the United States, whereas Celine is returning to university in Paris after visiting her grandmother. When they reach Vienna, Jesse convinces Celine to disembark with him, saying that 10 or 20 years down the road, she might not be happy with her marriage and might wonder how her life would have been different if she had picked another guy, and this is a chance to realize that he himself is not that different from the rest; in his words, he is "the same boring, unmotivated guy." Jesse has to catch a flight early in the morning and does not have enough money to rent a room for the night, so they decide to roam around in Vienna. After visiting a few landmarks in Vienna, they share a kiss at the top of the Wiener Riesenrad at sunset and start to feel a romantic connection. As they continue to roam around the city, they begin to talk more openly with each other, with conversations ranging from topics about love, life, religion, and their observations of the city. Celine tells Jesse that her last boyfriend broke up with her six months ago, claiming that she "loved him too much". When questioned, Jesse reveals he had initially come to Europe to spend time with his girlfriend who was studying in Madrid, but they had broken up when she was avoiding him while he was there. He decided to take a cheap flight home, via Vienna, but it did not leave for two weeks so he bought a Eurail pass and traveled around Europe. When they are walking alongside the Donaukanal (Danube canal) they are approached by a man who, instead of begging, offers to write them a poem with a word of their choice in it. Jesse and Celine decide on the word "milkshake", and are soon presented with the poem Delusion Angel (written for the film by the poet David Jewell). In a traditional Viennese cafe, Jesse and Celine stage fake phone conversations with each other, playing each other's friends they pretend to call. Celine reveals that she was ready to get off the train with Jesse before he convinced her. Jesse reveals that after he broke up with his girlfriend, he bought a flight that really was not much cheaper, and all he really wanted was an escape from his life. They admit their attraction to each other and how the night has made them feel, though they understand that they probably will not see each other again when they leave. They simply decide to make the best of what time they have left, ending the night with the implication of a sexual encounter between them. At that point, Jesse explains that if given the choice, he would marry her instead of never seeing her again. The film ends the next day at the train station, where, just as Celine's train is about to leave, the couple decides not to exchange any contact information but instead to meet at the same place in six months.

Answer: Strangers on a train, Jesse convinces Cline to disembark with him in what city?

Question: Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate (IM, Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), which specifically inhibits the autophosphorylation of the Abl TK, has improved the treatment of CML. However, resistance is often reported in patients with advanced-stage disease. Several novel TK inhibitors have been developed that override IM resistance mechanisms caused by point mutations within the Abl kinase domain. Inhibitors of Abl TK are divided into two main groups, namely, ATP-competitive and ATP noncompetitive inhibitors. The ATP-competitive inhibitors fall into two subclasses, the Src/Abl inhibitors, and the 2-phenylaminopyrimidine-based compounds. Dasatinib (formerly BMS-354825), AP23464, SKI-606, and PD166326 are classified as Src/Abl inhibitors, while nilotinib (AMN107) and INNO-406 (NS-187) belong to the latter subclass of inhibitors. Of these agents, dasatinib and nilotinib underwent clinical trials earlier than the others and favorable results are now accumulating. Clinical studies of the other compounds, including SKI-606 and INNO-406, have been performed in rapid succession. Because of their strong affinities for the ATP-binding site compared to IM, most ATP-competitive inhibitors may be effective in IM-resistant patients. However, an ATP-competitive inhibitor that can inhibit the phosphorylation of T315I Bcr-Abl has not yet been developed. Instead, ATP noncompetitive inhibitors, such as ON012380, Aurora kinase inhibitor MK0457 (VX-680), and p38 MAP kinase inhibitor BIRB-796, have been developed to address this problem. This review provides an update on the underlying pathophysiologies of disease progression and IM resistance, and discusses the development of new targeted TK inhibitors for managing CML and the importance of future strategies targeting CML stem cells.

Answer:
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?